Tarveda to Present Updates on the Development of Its Miniaturized Drug Conjugates at Upcoming Scientific and Medical Meetings
WATERTOWN, MA — July 17, 2017 — Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective cancer medicines, today announced that the company will present preclinical data related to its lead candidate, PEN-221, and provide an update on the Company’s novel Pentarin platform at upcoming scientific and medical meetings.
Gitanjali Sharma, Ph.D., will discuss the optimization of the formulation of PEN-221 leading to complete tumor regression in SSTR2-expressing cancer models, during a poster presentation at the 2017 Controlled Release Society Annual Meeting & Exposition in Boston.
Presentation title: Optimizing Stable Clinical Formulations for Miniaturized Drug Conjugates
Date and Time: 3:30pm to 4:00pm ET on Tuesday, July 18, 2017
Tarveda’s Chief Medical Officer, Leila Alland, M.D., will present Tarveda’s Pentarin platform and clinical stage programs at the 2017 Precision: Lung Cancer World R&D Summit in Boston.
Presentation Title: Developing Potent and Selective Miniaturized Conjugates for the Treatment of Patients With Solid Tumors
Date and Time: 11:30am to 12:00pm ET on Tuesday, July 25, 2017
Tarveda is developing Pentarins, potent and selective miniaturized drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell‑killing agent through an optimized chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for effective penetration and distribution into the tumor tissue, the ligand’s targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell‑killing payload inside the cancer cells for efficacy.
About Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc. discovers and develops Pentarins™, a new class of potent and selective miniaturized drug conjugates with enhanced targeting capabilities for the treatment of solid cancer tumors. Tarveda’s lead Pentarin drug candidate, PEN‑221, is a miniaturized drug conjugate that targets the somatostatin receptor 2 (SSTR2) for treatment of patients with neuroendocrine and small cell lung cancers. PEN-221 comprises a highly selective peptide that targets SSTR2 linked to the potent cytotoxic DM1 through a cleavable linker. Tarveda is also advancing its HSP90 drug conjugate platform with lead drug candidate PEN‑866, which is a miniaturized HSP90 targeting drug conjugate that comprises a small molecule HSP90 targeting ligand conjugated to SN‑38, the highly potent, active metabolite of irinotecan. Tarveda’s strategy includes developing its own proprietary Pentarins as well as applying the Pentarin platform to enhance the effectiveness of the targeting moieties and novel payloads of its pharmaceutical collaborators. www.tarveda.com
George E. MacDougall
MacDougall Biomedical Communications
781 235 3060